Drug Profile
Suvecaltamide - Merck & Co
Alternative Names: MK-8998Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Acetamides; Antipsychotics; Ethers; Fluorocarbons; Pyridines; Sleep disorder therapies; Small molecules
- Mechanism of Action T type calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizophrenia
- Discontinued Insomnia
Most Recent Events
- 23 Sep 2015 No recent reports on development identified - Phase-II for Schizophrenia in Ukraine, Serbia, Croatia and Russia (PO)